Clinical Trial Update: Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 open-label study evaluating long-term prolonged-release fampridine (BIIB041) and its effect on quality of life in people with multiple sclerosis; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• BIIB041 (prolonged-release fampridine) (dalfampridine)

Snippet

Sponsor: Biogen | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2016-11-04